Trial
NCT04585815
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
Sasanlimab Prefilled syringe
Why stopped
Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-09